Medical Reviews

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Hope TA¹, Bergsland E², Bozkurt MF³, Graham MM¹, Heaney AP⁴, Herrmann K³, Howe JR⁵, Kulke MH², Kunz PL², Mailman J¹, May L⁶, Metz DC⁵, Millo C¹, O’Dorisio S¹, Reidy-Lagunes DL², Soulen MC⁷, Strosberg JR²

J Nucl Med. 2017 Oct

68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis

Graham MM¹, Gu X², Ginader T³, Breheny P³, Sunderland JJ⁴

The Journal of Nuclear Medicine. 2017 September; 58(9): 1452-1458

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF

Pancreas. 2017 July; 46(6): 715-731

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK

Pancreas. 2017 July; 46(6): 707-714

Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results from a Large Patient Survey in the United States

Wolin EM, Leyden, J, Goldstein G, Kolarova T, Hollander R, Warner RRP

Pancreas. 2017 May/June; 46(5): 639-647

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC

JAMA Oncology. 2017 April [epub ahead of print]

Clinical, pathological and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors

Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih Y, Yao JC

Ann Oncol. 2017 April 21 [epub ahead of print]

Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement

Davar J¹, Connolly HM², Caplin ME³, Pavel M⁴, Zacks J⁵, Bhattacharyya S⁶, Cuthbertson DJ⁷, Dobson R⁸, Grozinsky-Glasberg S⁹, Steeds RP¹⁰, Dreyfus G¹¹, Pellikka PA², Toumpanakis C¹²

J Am Coll Cardiol. 2017 March ; 69(10): 1288-1304

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology — Neuroendocrine Tumors

Matthew H. Kulke, MD, Chair, et al

NCCN Clinical Practice Guidelines in Oncology. 2017 February; Version 1.2017: 1-116

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS; Cancer Genome Atlas Research Network, Pacak K, Nathanson KL, Wilkerson MD

Cancer Cell. 2017 Feb; 1(001): pii: S1535-6108(17)300001-6

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators

N Engl J Med. 2017 January; 376(2): 125-135

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Kulke MH¹, Hörsch D¹, Caplin ME¹, Anthony LB¹, Bergsland E¹, Öberg K^1, Welin S¹, Warner RR¹, Lombard-Bohas C¹, Kunz PL¹, Grande E¹, Valle JW1, Fleming D¹, Lapuerta P1, Banks P¹, Jackson S¹, Zambrowicz B1, Sands AT¹, Pavel M¹

Journal of Clinical Oncoloyg. 2016 October

Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors

Qian ZR1, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH

Pancreas. 2016 Sept

Development of Effective Prophylaxis against Intraoperative Carcinoid Crisis

Woltering EA¹, Wright AE², Stevens MA³, Wang YZ⁴, Boudreaux JP⁵, Mamikunian G⁶, Riopelle JM⁷, Kaye AD⁸

J Clin Anesth. 2016 Aug; 32: 189-93

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results from the First Global Survey of Patients with NETs

Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Oberg K, Leyden J

Journal of Global Oncology. 2016 June : 1-11

Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: An Evidence-Based Canadian Consensus

Singh S¹, Asa SL², Dey C³, Kennecke H⁴, Laidley D⁵, Law C⁶, Asmis T⁷, Chan D⁸, Ezzat S⁹, Goodwin R¹⁰, Mete O¹¹, Pasieka J¹², Rivera J¹³, Wong R¹⁴, Segelov E¹⁵, Rayson D¹⁶

Cancer Treat Rev. 2016 June; 47: 32-45

Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases

Kim MK¹, Ye F, Wang D, Cui M, Ward SC, Warner RR, Roayaie S, Shafir M, Schwartz M, Zhang D, Itzkowitz S.

Pancreas. 2016 April; 45(4): 528-532

Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum

Woltering EA¹, Beyer DT², Thiagarajan R³, Ramirez RA⁴, Wang YZ³, Ricks MJ⁴, Boudreaux JP³

J Am Coll Surg. 2016 April; 222(4): 534-42

Somatostatin Analogues in Neuroendocrine Tumors

Kulke, MH

J Natl Compr Canc Netw. 2016 March; 14(3): 241-242

Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

Modlin IM¹, Bodei L², Kidd M³.

Best Practice & Research Clinical Endocrinology & Metabolism. 2016 January; 30(1): 59-77

Consensus Guidelines for High Grade Gastro-Entero-Pancreatic (GEP) Neuroendocrine Tumours and Neuroendocrine Carcinomas (NEC)

Garcia-Carbonero R¹, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla J, Caplin M, O’Toole D, Perren A; all other Vienna Consensus Conference participants.

Neuroendocrinology. 2016 January {Epub ahead of print}

Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms (NEN)

Ramage J¹, De Herder WW, Delle Fave GF, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A; all other Vienna Consensus Conference participants.

Neuroendocrinology. 2016 January {Epub ahead of print}

Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

Pape UF¹, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O’Connor J, Krenning E, Reed N, O’Toole D; all other Vienna Consensus Conference participants.

Neuroendocrinology. 2016 January {Epub ahead of print}

Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

Pavel M¹, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; all other Vienna Consensus Conference participants

Neuroendocrinology. 2016 January {Epub ahead of print}

Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors

Khan TM¹, Garg M, Warner RR, Uhr JH, Divino CM.

Pancreas. 2015 Dec [epub ahead of print]

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study

Haugvik SP^1,2, Janson ET³, Österlund P⁴, Langer SW⁵, Falk RS⁶, Labori KJ⁷, Vestermark LW⁸, Grønbæk H⁹, Gladhaug IP^7,10, Sorbye H¹¹

Ann Surg Oncol. 2015 Dec [epub ahead of print]

Gastrointestinal Carcinoid Tumors (PDQ®): Treatment for Health Professionals

From the National Cancer Institute

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors

Phan AT, Kunz PL¹, Reidy-Lagunes DL

Clin Adv Hematol Oncol. 2015 May; 13(5 Suppl 5): 1-18; quiz 1 p following 18

Neuroendocrine tumors, version 1.2015

Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Jan 1; 13(1): 78-108

NCCN Clinical Practice Guidelines In Oncology, Neuroendocrine Tumors

National Comprehensive Cancer Network (NCCN). 2014 November: 1-108

Molecular pathology and genetics of gastrointestinal neuroendocrine tumors

Lewis MA, Yao JC

Curr Opin Endocrinol Diabetes Obes . 2014; 21(000-000): e-published ahead of print

Prospective of 68Ga-Radiopharmaceutical Development

Velikyan, Irina

Theranostics. 2014; 4(1): 47-80. doi: 10.7150/thno.7447

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Caplin ME, Pavel M, Ruszniewski P.

N Engl J Med. 2014 July; 371(16): 224-233

Recommendations for management of patients with neuroendocrine liver metastases

Frilling A1, Modlin IM2, Kidd M3, Russell C4, Breitenstein S5, Salem R6, Kwekkeboom D7, Lau WY8, Klersy C9, Vilgrain V10, Davidson B4, Siegler M11, Caplin M12, Solcia E9, Schilsky R13; Working Group on Neuroendocrine Liver Metastases.

Lancet Oncol. 2014 Jan; 15(1): e8-e21

Everolimus Plus Octreotide Long-Acting Repeatable in Patients with Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O’Dorisio T, Anthony LB, Hobday T

The Oncolgist. 2013; 18: 46-53

Practical Guide to Supportive Care of Patients With Functional Neuroendocrine Tumors

Anthony, Lowell B.

Semin Oncol. 2013; 40: 45-55

The Genomic Landscape of Small Intestine Neuroendocrine Tumors

Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, Eckloff BW, Wieben ED, Wu Y, Cunningham JM, Nagorney DM, Gilbert JA, Ames MM, Beutler AS

J Clin Invest. 2013 May 15

The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood

Irvin M. Modlin, Ignat Drozdov, Mark Kidd

PLOS One. 2013 May

Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned

Yao JC, Reidy Lagunes D, Kulke MH

The Oncologist. 2013 April 24

United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment.

trosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ

World J Gastroenterolo. 2013 April 21; 19(15): 2348-2354

Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options

Vicha A, Musil Z, Pacak K

Curr Opin Endocrinol Diabetes Obes. 2013 Mar 11

Advances in Pulmonary Neuroendocrine Tumor Management

Kjell Oberg

Advances in Pulmonary Neuroendocrine Tumor Management. 2013 March: doi: 10.2217/9781780841625 eISBN (PDF): 978-1-78084-162-5

Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma

Strosberg, JR

Semin Oncol. 2013 February; 40(1): 120-33

Are Neuroendocrine Tumors Going Mainstream?

Kulke, M

JCO. 2013 Feb 1; 31(4): 404-405 [Epub ahead of print]

Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours

International Atomic Energy Agency

IAEA Human Health Series. 2013

Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML

J Clin Endocrinol Metab. 2012 Jun 20; [Epub ahead of print]

The management of neuroendocrine tumours: current and future medical therapy options.

Oberg, KE

Clin Oncol (R Coll Radiol). 2012 May 24; 24(4): 282-93. Epub 2011 Sep 9.

Management of neuroendocrine tumors in children, adolescents, and young adults

Howell D, O’Dorisio MS

J Pediatr Hematol Oncol. 2012 May; 34(Supple 2): S64-68

The risk of metachronous cancers in patients with small intestinal carcinoid tumors: a US population-based study.

Amin S, Warner RR, Itzkowitz SH, Kim MK

Endocr Relat Cancer. 2012 Mar 27; [Epub ahead of print]

Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy.

Bousquet C, Lasfargues C, Chalabi M, Moatassim Billah S, Susini C, Vezzosi D, Caron P, Pyronnet S

J Clin Endocrinol Metab. 2011 Dec 14; [Epub ahead of print]

Management of Neuroendocrine Tumors of Unknown Origin

Polish A, Vergo MT, Agulnik M

J Natl Compr Canc Netw. 2011; 9(12): 1397-1403

Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.

Harring TR, Nguyen NT, Goss JA, O’Mahony CA

Int J Hepatol. 2011 Oct 13; 2011;2011:154541(doi: 10.4061/2011/154541)

A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract

Strosberg JR, Cheema A, Kvols, LK

Cancer Control. 2011 April; 18(2): 127-37

Targeted Radionuclide Therapy for Neuroendocrine Tumours: Principles and Application

Maralyn R. Drucea Val Lewingtonb Ashley B. Grossman

Neuroendocrinology. 2010; 91(1): 1-15. Epub 2009 Jul 7.

New Medical Strategies for Midgut Carcinoids

Ola Nilsson¹, Yvonne Arvidsson¹, Viktor Johanson², Eva Forssell-Aronsson³ and Håkan Ahlman²,*
Departments of Pathology¹, Surgery² and Radiation Physics³ at the   Sahlgrenska Academy, University of Gothenburg, Gothenburg,
Sweden

Anti-Cancer Agents in Medicinal Chemistry. 2010; 10: 250-269

Circulating Biomarkers in Neuroendocrine Tumors of the Enteropancreatic Tract: Application to Diagnosis, Monitoring Disease, and as Prognostic Indicators

Ardill JES, O’Dorisio TM

Endocrinol Metab Clin N Am 39 . 2010: 777-790

Paraneoplastic syndromes secondary to neuroendocrine tumours

Kaltsas G, Andoulakis II, de Herder WW, Grossman, AB

Endocrine-Related Cancer. 2010 Jul 28; 17(3): R173-R193 Print 2010 Sept

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM

Endocr Relat Cancer. 2010 Jun 25; 17(3): 623-36. Print 2010

Functional Imaging of NeuroendocrineTumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

Tina Binderup, Ulrich Knigge, Annika Loft, Jann Mortensen, Andreas Pfeifer, Birgitte Federspiel, Carsten Palnaes Hansen, Liselotte Højgaard, and Andreas Kjaer

Authors’ Affiliations: Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

J Nucl Med. 2010 May; 51: 704–712

Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth

Mackenzie R. Cook, Scott N. Pinchot, Renata Jaskula-Sztul, Jie Luo, Muthusamy Kunnimalaiyaan, and Herbert Chen

Authors’ Affiliations: Endocrine Surgery Research Laboratory, University of Wisconsin, and the University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Mol Cancer Ther. 2010 Jan 26; 9(2): 429–37

Biochemical testing for neuroendocrine tumors

Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M.
Eastern Virginia Medical School, Strelitz Diabetes Research Center,  Norfolk, VA 23510, USA

Pancreas. 2009 Nov; 38(8): 876-89

Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management, Fourth Edition (PDF file, full text, 259 pages)

Gregg Mamikunian, MS; Aaron I. Vinik, MD, PhD, FCP, MACP; Thomas M. O’Dorisio, MD; Eugene A. Woltering, MD, FACS; Vay Liang W. (Bill) Go, MD

Inter Science Institute. 2009

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Echocardiography

Ursula Plöckinger^a Björn Gustafsson^b Diana Ivan^c Waldemar Szpak^d
Joseph Davare^e and all other Mallorca Consensus Conference participants

^a Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany;
^b Medisinsk avd Gastroseksjon, St Olavs Hospital HF, Trondheim, Norway;
^c Endocrinology and Diabetology, Klinikum der Philipps-Universität, Marburg, Germany;
^d Westville Hospital, Amanzimototi, Mayville, South Africa;
^e Department of Cardiology, Royal Free Hospital, London, UK

Neuroendocrinology. 2009; 90: 190-193

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

Raymond E, Faivre S, Hammel P, Ruszniewski P

Department of Medical Oncology and Gastroenterology,
Beaujon University Hospital, Clichy, France,
eric.raymond@bjn.aphp.fr

Targeted Oncology . 2009; 4: 253-254

Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives

Gabriele Capursoa^a,1, Nicola Faziob^b,1, Stefano Festaa^a, Francesco Panzutoaa, Filippo De Braudbb, Gianfranco Delle Faveaa^a,*

^a Digestive and Liver Disease Unit, S. Andrea Hospital, II Medical School, University “La Sapienza”, Via Di Grottarossa 1035-1039, 00189, Rome, Italy

 ^b Unit of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy

Critical Reviews in Oncology/Hematology. 2009; 72: 110-124

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold, Thomas Gress, and Rudolf Arnold

Journal of Clinical Oncology. 2009 Oct 1; 27(28): 4656-63

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR

Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK.

Alimentary Pharmacology & Therapeutics Journal. 2009 Oct; 30(7): 733-40. Epub 2009 Jul 2.

Pancreatic neuroendocrine tumors: presentation, management, and outcomes

Nissen NN, Kim AS, Yu R, Wolin EM, Friedman ML, Lo SK, Wachsman AM, Colquhoun SD

Am Surg. 2009 October; 75(10): 1025-9

Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An Excellent Pair of Biomarkers for Diagnostics in Patients with Neuroendocrine Tumor

Catharina M. Korse, Babs G. Taal, Cornelis A. de Groot, Robert H. Bakker, and Johannes M.G. Bonfrer

Journal Clinical Oncology. 2009 Sep 10; 27: 4293-4299

Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors

Strosberg J, Nasir A, Coppola D, Wick M, Kvols L

Hum Pathol. 2009 Sep; 40(9): 1262-8. Epub 2009 Apr 14

Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules

Bushnell D.
University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.david-bushnell@uiowa.edu

Bushnell D. University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA. david-bushnell@uiowa.edu. 2009 Jul 7; 7(7): 760-4

Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome

Swärd C, Johanson V, Nieveen van Dijkum E, Jansson S, Nilsson O, Wängberg B, Ahlman H, Kölby L

British Journal of Surgery. 2009 May

NCI Carcinoid/NET Summit 2007; Main Conclusions

Irvin M. Modlin , Steven F. Moss , Daniel C. Chung , Robert T . Jensen , Elizabeth Snyderwine

J Natl Cancer Inst.. 2008 Sep 17; 100(18): 1282-1289

Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients

Woltering EA, Salvo VA, O’Dorisio TM, Lyons J 3rd, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P, Mamikunian G.

Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA. ewolte@lsuhsc.edu

Pancreas. 2008 Jul; 37(1): 94-100

Early and Late Results of Valvular Surgery for Carcinoid Heart Disease

Javier G. Castillo, Farzan Filsoufi, Parwis B. Rahmanian, Anelechi Anyanwu, Jerome S. Zacks, Richard R.P. Warner, David H. Adam

Journal of the American College of Cardiology. 2008 April 15; 51(15): 1507-1509

Bronchopulmonary Carcinoid: Phenotype and Long-term Outcome in a Single-Institution Series of Italian Patients

Massimo Rugge, Matteo Fassan, Roberto Clemente4, Giovanna Rizzardi,
Luciano Giacomelli, Gianmaria Pennelli, Claudia Mescoli1, Daniela Segat, and Federico Rea

Clinical Cancer Research. 2008 Jan 1; 14: 149-154. doi: 10.1158/1078-0432.CCR-07-1631

Population-based study of islet cell carcinoma

Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB. Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. jyao@mdanderson.org

Ann Surg Oncol. 2007 Dec; 14(12): 3492-500. Epub 2007 Sep 26.

Peptide receptor radionuclide therapy with (177) Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ

Eur J Nucl Med Mol Imaging . 2007; 34(8): 1219-1227

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Ekeblad S, Eriksson B, Sundin A, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Örlefors H, Sigurd M, Öberg K, Janson ET, Skogseid B

Clin Cancer Res. 2007; 13(10): 2986-2991

Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors

Muthusamy Kunnimalayaan, Herbert Chen

Endocrine Surgery Research Laboratories, Department of Surgery, The University of Wisconsin, and the University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA

The Oncologist . 2007; 12: 535–542

Response of atypical pulmonary carcinid tumors to chemotherapy. A retrospective study of 37 patients

Guigay J.
Poster presented at the12th World Conference on Lung Cancer, Seoul, Korea, September 2007.

Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells

Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, Chen H

F.A.C.S., H4/750 Clinical Science Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA.

Oncologist. 2007 Aug; 12(8): 942-51

Chemoembolization and Bland Embolization of Neuroendocrine Tumor Metastases to the Liver (Full text)

Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO.

Division of Interventional Radiology, University of Pennsylvania, 1 Silverstein, Philadelphia, PA 19104, USA

J Vasc Interv Radiol. 2007 Jul; 18(7): 847-55

Over expression of the Notch1 intracellular domain (NICD) inhibits cellular proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells

Muthusamy Kunnimalaiyaan, Abram M. Vaccaro, Mary A. Ndiaye, and Herbert Chen

J. Biol. Chem. 2006 Nov 7: 10.1074/jbc.M603578200

ENETS 2007 Consensus Guidelines for the Management pf Patients with Digestive Neuroendocrine tumors. Part1 Stomach, Duodenum and Pancreas

Wouter De Herder, Dermot O’Toole, Guido Rindi, Bertram Wiedenmann

Karger Neuro endocrinology . 2006; 84(3): 151-153

Diagnosis and Management of Neuroendocrine Tumors

by Rudolph Arnold, M.D., FRCP
8th United European Gastroenterology Week

Liver metastases of neuroendocrine tumors; early reduction of tumour load lead to improved life expectancy (full text)

Liesbeth M Veenendaal¹, Inne HM Borel Rinkes¹, Cornelis JM Lips²and Richard van Hillegersberg^*1, Netherlands.

World Journal of Surgical Oncology. 2006 Jun 26; 4: 35

Therapeutic Options for Gastrointestinal Carcinoids (Abstract)

Irvin M. Modlin, Igor Latich, Mark Kidd, Michelle Zikusoka, and Geeta Eick

Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520-8062, USA. imodlin@optonline.net

Clin Gastroenterol Hepatol. 2006 May; 4(5): 526-47

Surgery for Gastrinoma and Insulinoma in MEN 1 (Abstract)

Norton JA, Fang TD, Jensen RT

J Natl Compr Canc Netw. 2006 Feb; 4(2): 148-53

Goblet cell carcinoid of the appendix

Payam S Pahlavan¹  and Rani Kanthan²

¹Department of Physiology and Pathophysiology, University of  Heidelberg, Heidelberg, Germany

²Department of Pathology, University of Saskatchewan, Saskatoon, Canada

World Journal of Surgical Oncology. 2005; 3: 36

Biochemical assessment of niacin deficiency among carcinoid cancer patients.

Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR

Am J Gastroenterol. 2005 Oct; 100(10): 2307-14

Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors

Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR, Rashid A

Mod Pathol. 2005 Aug; 18(8): 1079-87

Enteroendocrine Tumors Other Than Carcinoid: A Review of Clinically Significant Advances

Richard R.P. Warner
Gastrointestinal Division, Department of Medicine
The Mount Sinai School of Medicine, New York, NY

Gastroenterology. 2005 May : 1668-1684

Current Status of Gastrointestinal Carcinoids

Irvin M. Modlin, Mark Kidd, Igor Latich, Michelle N. Zikusoka, and Michael D. Shapiro

Gastric Pathobiology Research Group, GI Surgical Division, Yale University School of Medicine, New Haven, Connecticut Revie

Gastroenterology. 2005 May; 128: 1717-1751

A Discussion on the Utility of Various Routes of Administration of Octreotide Acetate

Eugene A. Woltering MD FACS
The James D. Rives Professor of Surgery and Neurosciences
Louisiana State University Health Sciences Center
New Orleans LA 70065

Carcinoid tumor of the appendix in childhood: the experience of two Italian institutions

Dall’Igna P, Ferrari A, Luzzatto C, Bisogno G, Casanova M, Alaggio R, Terenziani M, Cecchetto G

J Pediatr Gastroenterol Nutr. 2005 Feb; 40(2): 216-9

Metastatic Carcinoid Tumors: A Clinical Review

Johann M. Zeutenhorst, Babs G. Taal

Oncologist. 2005 Feb; 10(2): 123-31

Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O’dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP

J Nucl Med. 2005 Jan; 46(1): 62S-6S

Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy

Wirth LJ, Carter MR, Jänne PA, Johnson BE

Lung Cancer. 2004; 44: 213-20

Considerations Concerning a Tailored, Individualized Therapeutic Management of Patients with (neuro)Endocrine Tumors of the Gastrointestinal Tract and Pancreas

W W de Herder, E P Krenning, C H J van Eijck 2 and S W J Lamberts

Endocrine-Related Cancer . 2004; 11: 19-34

The American Gastroenterological Association (AGA) Forum (2004)

American Gastroenterological Association

Carcinoid heart disease : presentation, diagnosis, and management

Fox DJ, Khattar RS

Heart. 2004 Oct; 90(10): 1224-8

Carcinoid heart disease: presentation, diagnosis, and management

Fox and Khattar

Heart. 2004; 90(10): p. 1224

Updated Population-Based Review of Carcinoid Tumors

By Maggard MA, O’Connell JB, Ko CY.

Anna Surg. 2004 Jul; 240(1): 117-22

Gastroenteropancreatic Neuroendocrine Tumor Disease: Molecular and Cell Biological Aspects

Edited by Bertram Wiedenmann; Gerhard M. Christofori; Michael Hoecker

Annals of the New York Academy of Sciences . 2004 April; 1014

Current Status of the Diagnosis and Treatment of Hereditary and Sporadic Neuroendocrine Tumors of the Gastroenteropancreatic System

European Neuroendocrine Tumor Society (ENETS), Budapest, March 2004
Neuroendocrinology 80 (suppl) 1 1-140(2004)
Editor B Wiedenmann, Publisher Karger
Access Author and Subject Index
Order information
Pictures from the Budapest conference

Neuroendocrinology . 2004 Mar; 80(1)

Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor

Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, Van Tinteren H, Taal BG

Cancer . 2003; 97: 1609-1615

Carcinoid Heart Disease

By Zuetenhorst JM, Taal BG.

N Engl J Med. 2003 Jun 5; 348(23): 2359-61

Additional references regarding treatment of patients with bronchial carcinoids

Provided by
Dan Granberg, MD, PhD, Consultant, Assistant Head of Department
Department of Endocrine Oncology
University Hospital
SE-751 85 Uppsala
Sweden

A 5-Decade Analysis of 13,715 Carcinoid Tumors

By Irving M. Modlin, M.D., Kevin D. Lys, M.D., Mark Kidd, Ph.D.

Cancer. 2003 Feb 15; 97(4): 934-59

A Carcinoid Tumor Associated with Chylous Ascites and Elevated Tumor Markers

Warner RR, Croen EC, Zaveri K, Ratner L

Int J Colorectal Dis. 2002 May; 17(3): 156-60

Carcinoid Tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment

Article by Oberg Kjell M.D.
Department of Medical Sciences, Uppsala University Hospital,
Uppsala, Sweden.

Current Opinion Oncology. 2002 Jan; 14(1): 38-45

Experience in treatment of metastatic pulmonary carcinoid tumors

Granberg D, Eriksson B, Wilander E, Grimfjärd P, Fjällskog M-L, Öberg K, Skogseid B. Experience in treatment of metastatic pulmonary carcinoid tumors.

Ann Oncol. 2001; 12(10): 1383-1391

Lung and thymic neuroendocrine tumors

Granberg D, Skogseid B

Doherty G, Skogseid B, eds. Surgical Endocrinology. Philadelphia. Lippincott Williams & Wilkins.. 2001: 413-430

Bronchial Carcinoid

By Dan Granberg M.D. : Bronchial Carcinoids.

Uppsala. 2001: 75p

Carcinoid and Pancreatic Endocrine Tumors: Recent advances in molecular pathogenesis, localization, and treatment

Jensen, RT

Curr Opin Oncol. 2000 Jul; 12(4): 368-77

Information on Carcinoid and Related Neuroendocrine Tumors

Several authors- collection of webpages